Bladerunner is absolutely correct. Cortex doesn't yet have a hi-impact in the clinic, and only North American (plus sundry) rights for the Servier compound--which has yet to complete a Phase I trial. They might get $5 million upfront for a high-impact deal that is strictly preclinical.
News 
Market Data 
Discover 
AI
